WO2024038378 - SUBSTITUTED PYRIDINONE COMPOUNDS AS CBL-B INHIBITORS
National phase entry:
Publication Number
WO/2024/038378
Publication Date
22.02.2024
International Application No.
PCT/IB2023/058197
International Filing Date
15.08.2023
Title **
[English]
SUBSTITUTED PYRIDINONE COMPOUNDS AS CBL-B INHIBITORS
[French]
COMPOSÉS DE PYRIDINONE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE CBL-B
Applicants **
GLENMARK PHARMACEUTICALS LTD
Inventors
CHINNAPATTU, Murugan
CHAUDHARI, Sachin
GOWDA, Nagaraj
DAS, Sanjib
IYER, Pravin
WAGHMARE, Nayan
SHELKE, Sandeep
GAVHANE, Balasaheb
SAINI, Jagmohan
KADAM, Sheetal
Priority Data
202221046493
16.08.2022
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5870 | |
| EPO | Filing, Examination, Granting | 92911 | |
| Japan | Filing, Examination, Granting | 4750 | |
| South Korea | Filing, Examination, Granting | 7177 | |
| USA | Filing, Examination, Granting | 64890 |
Total:
175,598
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful as CBL-b inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by CBL-b.[French]
La présente invention concerne des composés de formule (I) et des sels pharmaceutiquement acceptables de ceux-ci, qui sont utiles en tant qu'inhibiteurs de CBL-b, des procédés pour leur préparation, des compositions pharmaceutiques comprenant les composés, et l'utilisation des composés ou des compositions dans le traitement ou la prévention de maladies, d'affections et/ou de troubles divers à médiation par CBL-b